Eight studies reported the association between ERCC1 rs3212986 polymorphism and glioma risk, including 3008 glioma cases and 4319 controls (Table-I).11-18 11 studies reported the association between ERCC2 Lys751Gln polymorphism and glioma risk, including 3456 glioma cases and 4957 controls (Table-II).12-15,19-25 Six studies were conducted in Chinese population, and the other seven studies were conducted in Caucasian populations. Here, ERCC2 is linked to central nervous system cancer.